Member Info for Sangijuelas1

There will be no issues with the move to Nasdaq in the immediate term. If at some point in the future 4D opt to delist from Aim and exist only as ADRs, which I think they will, they will no longer be eligible for Isas and would need to be held in a general investment account. Some Sipps will also be problematic.
https://www.gov.uk/guidance/stocks-and-shares-investments-for-isa-managers#qualifying-investments-for-stocks-and-shares-isas

I am having to transfer Isa from Fidelity to AJ Bell as Fidelity would not be able to hold ADRs at all.

Worth checking out Verona Pharma chart (VRP. L) on Yahoo Finance over 5 years. They listed on Nasdaq in 2017.

In March 2018 they were worth 185. When they delisted they had been between 50-70p for 2 years

Potential future delisting from Aim which Mereo Bio and Verona Pharma recently did.

If only ADRs listed on Nasdaq difficult to hold in Isa or Sipp without UK listing although fine in general investment account.

Pancreatic cancer trial results still due for end Q4

There is a meeting scheduled with the FDA in Q1 to discuss accelerated approval for MRX 0518 which has been shown to extend life expectancy in stage 4 cancer patients with no other treatment options

Alex, how many of those other companies you mention have demonstrated proof of concept in oncology?

But at a much higher price and they pumped 5bn into them

Avacta

There was an article about Spac sponsors raking it in in the FT last week

Guess it comes down to trust in the board. No doubt a Nasdaq IPO would cost a lot more and require much more admin.

The main shareholders are the directors so they would be shafting themselves.

It looks like he has been looking into the facts. The likes of Chardan and Steve Oliveira are well known for pulling stunts like this.

From the RNS
Based on a price of £1.10 per 4D Ordinary Share, the 4D Ordinary Shares underlying the 4D ADSs to be issued in exchange for each Longevity Share in the Merger represent an aggregate value of approximately US$26.1 million.

So they are getting 26.1m dollars worth of shares for 14m

During a presentation with Chardan in March Duncan was asked what is the main thing that the market is missing with 4D.

He answered that it is the immediacy of LBTs which can be rapidly discovered on the Micro RX platform and rapidly taken through development due to their safety profile. So what would normally take longer with traditional drug candidates can be done on an accelerated timescale.

Hence the scheduled meeting with the FDA in Q1

Preliminary results for the trial of MRX 0518 in pancreatic cancer patients were also scheduled for Q4 2020. This is ongoing at MD Andersen in Texas.
Hopefully these will come in the next few weeks

Of the posters on here will be off once they have made back some of the loss from getting spiked a couple of months back from the pump and dump operation

This is what Merck does when they are serious about a partnership. And compare it to the piddling £5m stake they took out in 4D

https://www.bloomberg.com/news/articles/2020-09-14/merck-inks-up-to-4-5-billion-cancer-deal-with-seattle-genetics

Maybe direct your anger to the delusional fantasists talking nonsense about a non existent takeover.

I see myself as a business owner rather than a shareholder.

It is clear that hardly anyone on here has got any idea what they currently own.

No one wants to be the owner of shares in the world leader in live biotherapeutics - a revolutionary new branch of medicine that will help treat people with multiple conditions without the risk of side effects.

Get rich or die trying